ACADIA price target raised to $42 from $28 at Piper Jaffray Piper Jaffray raised its price target for ACADIA Pharmaceuticals to $42 citing the company's pipeline progress following its Q4 results. The firm keeps an Overweight rating on the stock.
Cowen to hold a conference 35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
ACADIA price target raised to $50 from $31 at JMP Securities JMP Securities increased its price target on ACADIA based on its higher sales estimates for the company's anti-psychotic drug, NUPLAZID, after the company raised the price of the drug. The firm reiterates an Outperform rating on the shares.